WO2022091122A1 - Stable remdesivir formulations - Google Patents
Stable remdesivir formulations Download PDFInfo
- Publication number
- WO2022091122A1 WO2022091122A1 PCT/IN2021/051012 IN2021051012W WO2022091122A1 WO 2022091122 A1 WO2022091122 A1 WO 2022091122A1 IN 2021051012 W IN2021051012 W IN 2021051012W WO 2022091122 A1 WO2022091122 A1 WO 2022091122A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- pharmaceutical composition
- composition according
- remdesivir
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 145
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 title claims abstract description 83
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 title claims abstract description 74
- 238000009472 formulation Methods 0.000 title abstract description 103
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 13
- 229940097362 cyclodextrins Drugs 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 239000004094 surface-active agent Substances 0.000 claims description 24
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 23
- 229920000053 polysorbate 80 Polymers 0.000 claims description 23
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 22
- 229940068968 polysorbate 80 Drugs 0.000 claims description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 239000006184 cosolvent Substances 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 238000003860 storage Methods 0.000 claims description 17
- 208000025721 COVID-19 Diseases 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- -1 t-butyric acid Chemical compound 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000006172 buffering agent Substances 0.000 claims description 8
- 235000015165 citric acid Nutrition 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 125000005456 glyceride group Chemical group 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 2
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 claims description 2
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical class CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 229940097043 glucuronic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 239000002357 osmotic agent Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 abstract description 5
- 239000000651 prodrug Substances 0.000 abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000001556 precipitation Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 238000001802 infusion Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 229940126222 Veklury Drugs 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 3
- 229940126656 GS-4224 Drugs 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 229920002675 Polyoxyl Polymers 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- 101100460513 Caenorhabditis elegans nlt-1 gene Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- PSQFOYNNWBCJMY-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCOCCOCCO PSQFOYNNWBCJMY-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- ONJPCDHZCFGTSI-NJYHNNHUSA-N CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1O Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1O ONJPCDHZCFGTSI-NJYHNNHUSA-N 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000030156 Marburg disease Diseases 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 229920002516 Poloxamer 331 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920002696 Polyoxyl 40 castor oil Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940122423 Viral RNA polymerase inhibitor Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- NPTLAYTZMHJJDP-KTKRTIGZSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO NPTLAYTZMHJJDP-KTKRTIGZSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940108759 amiodarone injection Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- DJINZKSHLUSBEQ-UHFFFAOYSA-N boric acid;2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OB(O)O.OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O DJINZKSHLUSBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- CITHEXJVPOWHKC-UHFFFAOYSA-N dimyristoyl phosphatidylcholine Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940089666 egg yolk phosphatides Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012632 extractable Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940113164 trimyristin Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the invention is directed to stable formulations of nucleotide analogue prodrug, in particular Remdesivir in the form of cyclodextrin-free ready-to-use solution and ready-to-dilute concentrates for the treatment of COVID-19.
- Each 100 mg of lyophilized powder and solution of remdesivir contain 3g and 6g of SBECD respectively which maintains remdesvir in solution form thus avoiding precipitation of the drug during its shelf life and in-use storage.
- each 100 mg of lyophilized powder as well as solution of remdesivir requires dilution with 0.9% sodium chloride solution requiring multiple solution transfer prior to intravenous administration.
- the diluted solution needs to be prepared under aseptic conditions and on same day as administration.
- the reconstituted product needs to be used immediately to prepare the diluted drug product. Any unused portion remaining in the reconstituted vial needs to be discarded since after a diluted solution is prepared the product contains no preservative. Any unused portion of a single-dose VEKLURY vial also needs to be discarded.
- Another object of the invention is to provide ready-to-use and/or ready-to-dilute composition
- remdesivir or its pharmaceutically acceptable salts, surfactants and optionally pharmaceutically acceptable excipients comprising remdesivir or its pharmaceutically acceptable salts, surfactants and optionally pharmaceutically acceptable excipients.
- a composition comprising the antiviral nucleotide analogue prodrug, in particular remdesivir would otherwise have experienced issues such as insolubility and relative chemical instability in aqueous media that are attributed to remdesivir, however, a suitable pharmaceutical composition is disclosed in a PCT application viz. WO2019014247 which provides a parenteral composition of remdesivir which comprises cyclodextrins whereby the composition exhibits improved solubility, improved usability for parenteral administration, and sufficient room-temperature and elevated temperature stability to avoid the use of cold-chain for transport and/or storage.
- beta-cyclodextrin derivatives are known to have certain physiological effects on kidneys.
- Remdesivir as used herein is denoted in broad sense to include not only “Remdesivir” per se but also its pharmaceutically acceptable derivatives thereof.
- suitable pharmaceutically acceptable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
- ready-to-dilute refers to a formulation which can be directly combined with a diluent (e.g., dextrose solution, saline solution, or any other infusion medium) and then administered to a patient.
- a diluent e.g., dextrose solution, saline solution, or any other infusion medium
- the ready-to- dilute formulation may be provided as a single vial containing the remdesivir formulation.
- the ready-to-dilute formulation may be accompanied by a pharmaceutically acceptable diluent in a separate container (i.e., a dual vial formulation).
- concentration of remdesivir in the ready-to-dilute formulation is about 5 mg/mL
- the solution of remdesivir of present invention remains physically stable, with no precipitation or crystallization or color change upon storage and the value of percentage transmittance of the solution remaining greater than 90%, preferably greater than 95% for the shelf life period of 18-24 months when stored at room temperature.
- compositions of the present invention may optionally include a buffer.
- General and biological buffers in the pH range of about 2.0 to about 8.0 include, but are not limited to, acetate, borate, citrate, collidine, formate, maleate, Mcllvaine, phosphate, Prideaux-Ward, succinate, citrate -phosphate -borate buffers.
- Suitable osmotic adjusting agents that may be used include, but are not limited to, sodium chloride, dextrose, sucrose and mixtures thereof.
- Other osmotic adjusting agents may also include, but are not limited to, mannitol, glycerol, propylene glycol and mixtures thereof.
- Formulation containing high concentration of surfactant in the formulation did not exhibit precipitation upon dilution in normal saline but these formulations contained large amounts of Polysorbate 80 which could be associated with toxicity. In formulation containing low or no Polysorbate 80 concentration, the formulation had tendency for precipitation of remdesivir during storage. Hence, appropriate concentration of surfactant was necessary to maintain remdesivir in solution state during shelflife of the product and in-use period while limiting the daily intake well within the level of Polysorbate 80 approved in the other marketed products is necessary.
- the formulations may include one or more buffering agents.
- the buffering agent comprises a Cl-6alkyl carboxylic acid, for instance formic acid, acetic acid, 1 -propionic acid, 2-propionic acid, n-butyric acid, t-butyric acid, isobutyric acid, or sec-butyric acid.
- the buffering agent comprises a hydroxy substituted-carboxylic acid or polycarboxylic acid, e.g., a compound having two or more carboxylic acid functional groups.
- Such compounds include, for instance, lactic acid, glycolic acid, 3 -hydroxypropionic acid, hydroxylbutyric acid, malonic acid, succinic acid, malic acid, tartaric acid, citric acid, fumaric acid, muramic acid, gluconic acid and glucuronic acid.
- compositions (Formula -1 & Formula 2) with 26% Polysorbate 80 would corresponds to a daily intake of about 10.4 g of Polysorbate 80.
- An intake of ⁇ 4.5g/day is preferred considering the level of Polysorbate 80 approved in the marketed products.
- Table 5 provides comparative stability of the prototype formula - 6 at different solution pH and a formulation manufactured using quantitative formula provided in label of Reference product, Veklury® at room temperature conditions. Table 5. Comparative Stability data of Cyclodextrin- free formulations at room temperature conditions (25°C/60%RH) in inverted orientation
Abstract
The invention is directed to stable formulations of nucleotide analogue prodrug, in particular remdesivir in the form of ready-to-use (RTU) and ready-to-dilute (RTD) formulations which are free of cyclodextrins.
Description
STABLE REMDESIVIR FORMULATIONS
CROSS-REFERENCE TO RELATED APPLICATIONS:
This application claims priority to Indian Application No. 202021046615, filed 26th October, 2020 and entitled “STABLE REMDESIVIR FORMULATIONS” which is incorporated herein in its entirety.
FIELD OF INVENTION:
The invention is directed to stable formulations of nucleotide analogue prodrug, in particular Remdesivir in the form of cyclodextrin-free ready-to-use solution and ready-to-dilute concentrates for the treatment of COVID-19.
BACKGROUND AND PRIOR ART:
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease of potential zoonotic origin. Severe acute respiratory syndrome (SARS) corona virus- 2, (SARS-CoV-2), the etiological agent of COVID-19, can cause a serious or lifethreatening disease or condition, including severe respiratory illness. The public health concerns caused by the outbreak of COVID-19 was declared as a “public health emergency of international concern” on 31 January and “pandemic on 11 March 2020 by World Health Organization. Impacts of the COVID-19 pandemic are currently ‘skyrocketing’ across the globe, causing enormous public health havoc and a colossal economic crisis.
The spread of COVID-19 is so accelerating that it needed 67 days from the first diagnosed case to reach the first 100,000 cases, 11 days for the second 100,000 cases, 4 days for the third 100,000 cases, 3 days for the fourth 100,000 cases and just extra 7 days for additional 400,000 cases around the globe. A similar pattern has been seen in the fatality as it required 17 days from the first death reported on 11 January 2020 to reach the first 100 deaths, 30 days for the 1,000 deaths, 61 days for the 5,000 deaths and 68 days for 10,000 deaths and just 9 additional days for additional 20,000 deaths. By 1 April 2020, the number of confirmed cases
skyrocketed to approximately 823,000 and 40,598 deaths from 205 countries and territories around the globe. In the single day of 31 March, there were approximately 72,700 new confirmed cases and 4,193 deaths reported across the world. The reported mortality rate for COVID-19 is around 3% and the mortality rates vary depending on geographical regions, age distributions and co-morbidities. With the advent of the devastating pandemic, many clinical trials have been initiated, and couple of them are pursuing already known drugs and evaluating whether such known drugs could be re-purposed towards alleviating and/ or treating the symptoms associated with COVID-19 patients.
Remdesivir was discovered by Gilead Sciences Inc., however, Gilead Sciences originally developed this drug to eliminate Ebola virus and Marburg virus infection. In vitro tests have shown that Remdesivir is not only effective against Ebola virus and other filoviruses, but also against respiratory syncytial virus, coronavirus, Nipah virus, Hendra virus, and atypical pneumonia (SARS-CoV) and Middle East Respiratory Syndrome (MERS-CoV) virus pathogens.
Remdesivir has been the only drug which is approved by FDA for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.
Remdesivir is available as VEKLURY for injection, 100 mg, is a sterile, preservative-free lyophilized powder that is to be reconstituted with 19 mL of Sterile Water for Injection and further diluted into 0.9% sodium chloride infusion bag prior to administration by intravenous infusion and is also available as VEKLURY (remdesivir) injection 100 mg/20 mL (5 mg/mL) that is to be diluted into 0.9% sodium chloride infusion bag prior to administration by intravenous infusion.
The inactive ingredients of both these formulations contain Betadex Sulfobutyl Ether Sodium also known as sulfobutylether-P-cyclodextrin sodium salt (SBECD),
water for injection and may include hydrochloric acid and/or sodium hydroxide for pH adjustment.
Because remdesivir has limited water solubility, the intravenous preparation contains the solubilizer, SBECD. SBECD is a large, cyclic oligosaccharide that is predominantly excreted through glomerular filtration with a ti/2 elimination of 2 hours in patients with normal kidney function. Animal studies have associated SBECD accumulation with liver necrosis and renal tubule obstruction, which occurred in animals at doses 50- to 100-fold higher than expected for a 5- to 10-day remdesivir course.
Each 100 mg of lyophilized powder and solution of remdesivir contain 3g and 6g of SBECD respectively which maintains remdesvir in solution form thus avoiding precipitation of the drug during its shelf life and in-use storage.
Although the approved formulations may seem to contain higher quantity of SBECD, the quantity of SBECD is well below the maximum recommended safety threshold dose of 250 mg/kg per day of SBECD. In spite of this, remdesivir is not recommended in adults and pediatric patients (>28 days old) with eGFR less than 30 mL per minute or in full-term neonates (>7 days and <28 days old) with serum creatinine >1 mg/dL.
Further, each 100 mg of lyophilized powder as well as solution of remdesivir requires dilution with 0.9% sodium chloride solution requiring multiple solution transfer prior to intravenous administration. Also, the diluted solution needs to be prepared under aseptic conditions and on same day as administration. Further, the reconstituted product needs to be used immediately to prepare the diluted drug product. Any unused portion remaining in the reconstituted vial needs to be discarded since after a diluted solution is prepared the product contains no preservative. Any unused portion of a single-dose VEKLURY vial also needs to be discarded.
Hence, there is a need to develop a formulation of Remdesivir which is safe for administration to all categories of patients as well as which is cost effective, which can be produced by simple manufacturing techniques, exhibits better or improved bioavailability, which can be stored for a longer period of time and moreover which provides patient compliance as well as is free of side effects.
OBJECT OF THE INVENTION:
An object of the invention is to provide stabilized, ready -to-use, remdesivir compositions.
Another object of the invention is to provide stabilized, ready -to-dilute, remdesivir compositions.
Yet another object of the invention is to provide stabilized, ready-to-use and/or ready -to-dilute, remdesivir compositions free of Betadex Sulfobutyl Ether Sodium (SBECD).
Another object of the invention is to provide ready-to-use and/or ready-to-dilute composition comprising remdesivir or its pharmaceutically acceptable salts, surfactants and optionally pharmaceutically acceptable excipients.
Another object of the invention is to provide a process for preparing stabilized, ready-to-use, remdesivir compositions.
Yet another object of the invention is to provide a process for preparing stabilized, ready-to-dilute, remdesivir compositions.
Another object of the invention is to provide a process for preparing stabilized, ready-to-use and/or ready-to-dilute, remdesivir compositions free of Betadex Sulfobutyl Ether Sodium (SBECD).
One another object of the present invention is to provide safe, efficacious and easy to use compositions of remdesivir.
Another object of the present invention to provide a method of treating COVID-19 by administering stable ready-to-use and ready-to-dilute parenteral compositions of remdesivir.
SUMMARY OF THE INVENTION:
In some embodiments, the compositions of the present invention do not include Betadex Sulfobutyl Ether Sodium (SBECD) or any cyclodextrin compounds. In an embodiment, the compositions of the present invention are in the form of ready -to- use solution and/or ready-to-dilute concentrates.
According to some embodiments of the present invention the ready-to-use and/or ready-to-dilute composition comprising remdesivir or its pharmaceutically acceptable salts, surfactants and optionally pharmaceutically acceptable excipients is provided.
According to some embodiments, the composition can be a composition of remdesivir, ready for direct introduction into an infusion bag.
According to some embodiments, the composition can be a ready-to-use composition of remdesivir that can be directly administered to patient without first combining with a pharmaceutically acceptable diluent.
Also disclosed herein are processes for preparation of ready-to-use and/or ready-to- dilute formulations of remdesivir.
Also disclosed herein are method for treating COVID-19 by parenterally administering ready-to-use and/or ready-to-dilute composition of remdesivir.
DETAILED DESCRIPTION OF THE INVENTION:
The antiviral nucleotide analogue prodrug, in particular remdesivir, chemically referred as (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,l- f][l,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2- yl)methoxy)(phenoxy) phosphoryl)amino)propanoate, referred to herein as Compound 1, is a viral RNA polymerase inhibitor and is known to exhibit antiviral properties against Arenaviridae, Coronaviridae, Filoviridae, and Paramyxoviridae
viruses as described in Warren, T. et al, Nature (2016) 531 :381-385, and antiviral activities against Flaviviridae viruses as described in co-pending International Publication No. WO2016/069826 and WO 2017/184668. The CAS Registry Number for Compound 1 is 1809249-37-3.
[Compound 1]
A composition comprising the antiviral nucleotide analogue prodrug, in particular remdesivir would otherwise have experienced issues such as insolubility and relative chemical instability in aqueous media that are attributed to remdesivir, however, a suitable pharmaceutical composition is disclosed in a PCT application viz. WO2019014247 which provides a parenteral composition of remdesivir which comprises cyclodextrins whereby the composition exhibits improved solubility, improved usability for parenteral administration, and sufficient room-temperature and elevated temperature stability to avoid the use of cold-chain for transport and/or storage. However, beta-cyclodextrin derivatives are known to have certain physiological effects on kidneys.
The WO2019014247 application acknowledges that certain solubilizers may be used to improve the solubility of a compound to form a composition capable of being administered parenterally, however such solubilizers may have certain undesirable effects (Stella, et. al. Toxicologic Pathology (2008), Vol 36, Number 1, pages 30-42). For example, a formulation including polysorbate 80 may have potential hemodynamic effects, tubing limitations, extractables and leachables from tubing, limitations on stoppers, potential for precipitation upon dilution, or issues with adaptability for pediatric use. As another example, beta-cyclodextrin
derivatives are known to have certain physiological effects on kidneys, thus there is also a need to limit the amount of such solubilizers in a pharmaceutical formulation. This application also explored pre -concentrate formulations comprising a surfactant and organic solvents. A solution formulation comprising Remdesivir present in about 30 mg/ mL in 25 % TWEEN® 80, 50 % PEG 300, and 25 % water was evaluated, but showed precipitation upon lOx and lOOx dilution in normal saline. Other explored formulations included solution formulations comprising Remdesivir present in about 5 mg / mL in 25 % Tween 80, 25 % PEG 300, 50 % water and another solution formulation comprising Compound 1 present at about 5 mg / mL in 25 % TWEEN® 80, 75 % water. These other formulations did not exhibit precipitation upon dilution in normal saline but would require larger amounts of TWEEN® 80 which could be associated with toxicity.
Given the shortcomings in the existing approach and to overcome the toxic and side effects, the inventors of the present invention have developed stable pharmaceutical composition comprising remdesivir along with pharmaceutically acceptable excipients which is safe for administration to all categories of patients, exhibits better or improved bioavailability, can be stored for long period of time, provides patient compliance as well as are free of side effects.
In particular, the inventors of the present invention have developed a stable remedesivir formulation by optimizing the concentrations of certain excipients, wherein the formulation remedesivir remains stable without exhibiting any precipitation as well as would render the said formulation safe for administration. As used in this specification, whether in a transitional phrase or in the body of the claim, the terms “comprise(s)” and “comprising” are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases “having at least” or “including at least”. When used in the context of a process, the term “comprising” means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term “comprising” means that the compound or composition
includes at least the recited features or components, but may also include additional features or components.
As used in this specification, the singular forms “a,” “an” and “the” specifically also encompass the plural forms of the terms to which they refer, unless the content clearly dictates otherwise.
The term “about” is used herein to mean approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20%.
It will be well appreciated that the term “Remdesivir” as used herein is denoted in broad sense to include not only “Remdesivir” per se but also its pharmaceutically acceptable derivatives thereof. Suitable pharmaceutically acceptable derivatives include pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable anhydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable esters, pharmaceutically acceptable isomers, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable tautomers, pharmaceutically acceptable complexes etc.
As used herein, the term " Remdesivir " refers to the above referred Compound 1 as discussed above which is incorporated herein by reference. This term may relate either to the free form of remdesivir or to any pharmaceutically acceptable salt thereof.
The term "treating" or "treatment" as used herein refers to relieving, reducing or alleviating at least one symptom in a subject or effecting a delay of progression of a disease. For example, treatment can be the diminishment of one or several
symptoms of a disorder or complete eradication of a disorder, such as cancer. Within the meaning of the present invention, the term "treat" also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
The term "pharmaceutically acceptable salt" refers to a charged species of the parent compound and its counter ion, which is typically used to modify the solubility characteristics of the parent compound and/or to reduce any significant irritation to an organism by the parent compound, while not abrogating the biological activity and properties of the administered compound. Examples, without limitation, of pharmaceutically acceptable salts include salts comprising an anion such as a carboxylate or sulfate anion, and/or a cation such as, but not limited to, ammonium, sodium, potassium, and the like. Suitable salts are described in, e.g., Birge et al. [J Pharma Sci 1977, 66: 1-19],
The term "pharmaceutical composition" or “pharmaceutical formulation” or similar term combination refers to a formulation of remdesivir described herein with pharmaceutically acceptable carriers and excipients.
The term "pharmaceutically acceptable carrier" refers to a carrier, adjuvant, or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
The term “excipient(s)" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include surfactants, isotonicity agents, pH adjusters, buffers, preservatives, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
The disclosed formulations of the present invention are particularly suited for injection, but it will be understood that the solutions may have alternative uses.
Injectable formulations may be administered via any route including intramuscular, intravenous, or subcutaneous.
The formulations can be in the form of liquid concentrates, ready -to-dilute and/or ready-to-use solutions. The ready-to-dilute and ready-to-use formulations may be packaged within a conventional sterile vial or other container. Alternatively, the formulations may be packaged in a sterile syringe already fitted with a needle for injection.
The term “ready-to-use” refers to any preparation of remdesivir which can be administered to patient directly without any further dilution or processing. The concentration of remdesivir in the ready-to-use formulation is about 1 mg/mL
The term “ready-to-dilute” refers to a formulation which can be directly combined with a diluent (e.g., dextrose solution, saline solution, or any other infusion medium) and then administered to a patient. In some embodiments, the ready-to- dilute formulation may be provided as a single vial containing the remdesivir formulation. In other embodiments, the ready-to-dilute formulation may be accompanied by a pharmaceutically acceptable diluent in a separate container (i.e., a dual vial formulation). The concentration of remdesivir in the ready-to-dilute formulation is about 5 mg/mL
The term “ready-to-dilute” is distinguished from lyophilized products that require two steps, a first step of reconstitution to form a preconcentrate and then a second step where the preconcentrate is subjected to dilution with an aqueous infusion fluid. The ready- to- dilute parenteral formulation according to the present invention avoids the inconvenience of reconstituting a concentrated parenteral formulation into infusion diluents prior to infusion, as well as eliminates the risk of any potential calculation or dilution error as well as risk of microbiological contamination during handling. The volume of the aqueous drug solution according to the present invention is large i.e. when the end use container used in ‘ready-to-dilute’ parenteral dosage form is a prefilled syringe, then the volume of the aqueous solution may be
about 50 ml to 100 ml. When the end use container is infusion bag, the volume of the aqueous solution may be about 100 ml to 500 ml.
The term "stable formulations" refers that remdesivir formulations of present invention are physically as well as chemically stable as demonstrated by compliance to acceptable specification when the formulation is stored at convenient temperature, such as between about 0°C and about 60°C, for a commercially reasonable period of time, such as at least about 1 day, at least about 1 week, at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year, or at least about 2 years. For purposes of the present invention, “long term storage' shall be understood to include at least time periods which are in excess of those observed when currently available lyophilized remdesivir formulations are reconstituted. Suitably, the solution of remdesivir of present invention remains physically stable, with no precipitation or crystallization or color change upon storage and the value of percentage transmittance of the solution remaining greater than 90%, preferably greater than 95% for the shelf life period of 18-24 months when stored at room temperature.
According to the present invention, there is provided a pharmaceutical composition administered by injection comprising remdesivir along with one or more pharmaceutically acceptable carriers as defined hereinabove.
The pharmaceutical compositions of the invention may optionally comprise one or more pharmaceutically acceptable excipients, such as a pH adjusting agent, buffer, osmotic agent, surfactant, antioxidant, preservative, and/or isotonicity agent. The use of said pharmaceutically acceptable excipients in appropriate amounts or quantity can be readily determined by any person with ordinary skill in the art.
The pharmaceutical compositions of the present invention have a pH of about 3 to about 7. The pH may be adjusted by the addition of one or more pharmaceutically acceptable acids. Examples of suitable pharmaceutically acceptable acids include
inorganic acids, such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid, and combinations thereof. Examples of other suitable pharmacologically acceptable acids include organic acids, such as ascorbic acid, citric acid, malic acid, maleic acid, tartaric acid, succinic acid, fumaric acid, acetic acid, formic acid, and/or propionic acid or other than acid variants which comprises sodium hydroxide. In one embodiment, the pH is adjusted with IN hydrochloric acid or sodium hydroxide. In another embodiment, the pH is adjusted with one or more organic acids selected from citric acid, ascorbic acid, fumaric acid and acetic acid.
The pharmaceutical compositions of the present invention may optionally include a buffer. General and biological buffers in the pH range of about 2.0 to about 8.0 include, but are not limited to, acetate, borate, citrate, collidine, formate, maleate, Mcllvaine, phosphate, Prideaux-Ward, succinate, citrate -phosphate -borate buffers. Suitable osmotic adjusting agents that may be used include, but are not limited to, sodium chloride, dextrose, sucrose and mixtures thereof. Other osmotic adjusting agents may also include, but are not limited to, mannitol, glycerol, propylene glycol and mixtures thereof.
The pharmaceutical compositions can include one or more pharmaceutically acceptable surfactants. Suitable surfactants include anionic, cationic, amphoteric and non-ionic surfactants, Pharmaceutically acceptable surfactant for this application include, but are not limited to, polysorbate or polyethoxylated castor oil, Polyoxyl 20 stearate, Polyoxyl 35 castor oil, pol oxamer, polyoxyethylene sorbitan monoisostearate, polyethylene glycol 40 sorbitan diisostearate, Polyoxyl 40 Hydrogenated castor oil, Polysorbate, Polysorbate 20, Polysorbate 40, Polyoxyl 60 stearate, Polysorbate 85, Polysorbate 60, poloxamer 331, polyoxyethylene fatty acid esters, Polyoxyl 40 castor oil, poloxamer 188, polyoxyethylene poly oxypropylene 1800, oleic acid, Sodium desoxy cholate, Sodium lauryl sulfate, Sorbitan monolaurate, Sorbitan monooleate, Sorbitan monopalmitate, Sorbitan trioleate, N-Carbamoyl methoxypolyethylene glycol 2000-1,2-distearol, myristic
acid, Steareth, Stearic acid, Polyoxyl 40 stearate, Sucrose stearate, Tocopherol, polyoxyl castor oil, Triglyceride synthetic, Trimyristin, Tristearin, magnesium stearate, lecithin, lauryl sulfate, Vitamin E, egg yolk phosphatides, docusate sodium, Polysorbate 80, dimyristoyl phosphatidylglycerol, dimyristoyl lecithin, Capryol 90 (propylene glycol monocaprylate), Capryol PGMC (propylene glycol monocaprylate), deoxycholate, cholesterol, Cremophor EL, Propylene glycol alginate, Croval A- 10 (PEG 60 almond glycerides), Labrafil 1944 (oleoyl macrogol-6 glycerides), Labrafil 2125 (linoleoyl macrogol-6 glycerides), Labrasol (capryl ocaproyl macrogol-8 glycerides), Lauroglycol 90 (propylene glycol monolaurate), Lauroglycol FCC (propylene glycol laurate), calcium stearate, Lecithin Centromix E, Lecithin Centrophase 152, Lecithin Centrol 3F21B, POE 26 glycerin, Olepal isosteariques (PEG-6 isostearate), Plurol diisostearique (polyglycerol-3-diisostearate), Plurol Oleique CC, POE 20 Sorbitan trioleate, Tagat TO (polyoxyethylene glycerol trioleate), or Solutol (macrogol-15 hydroxystearate). Preferably, the surfactant included in composition of present invention is Polysorbate 80.
In some ready-to-dilute (pre concentrate) embodiments, the surfactant can be present in an about 5% to about 30% of the total weight of the formulation, preferably from about 6% to about 25% of the total weight of the formulation, more preferably from about 7% to about 20% of the total weight of the formulation and most preferably from about 8% to about 12% of the total weight of the formulation. In some ready -to-administer/use (RTU) embodiments, the surfactant can be present in an about 1% to about 6% of the total weight of the formulation, preferably from about 1.5% to about 4% of the total weight of the formulation, more preferably from about 1.5% to about 3% of the total weight of the formulation and most preferably from about 1.5% to about 2.5% of the total weight of the formulation.
Formulation containing high concentration of surfactant in the formulation did not exhibit precipitation upon dilution in normal saline but these formulations contained large amounts of Polysorbate 80 which could be associated with toxicity.
In formulation containing low or no Polysorbate 80 concentration, the formulation had tendency for precipitation of remdesivir during storage. Hence, appropriate concentration of surfactant was necessary to maintain remdesivir in solution state during shelflife of the product and in-use period while limiting the daily intake well within the level of Polysorbate 80 approved in the other marketed products is necessary.
The pharmaceutically acceptable co-solvent system may comprise at least one pharmaceutically acceptable, water miscible organic solvents. In some embodiments, the compositions can include ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerol, dimethylacetamide, N- methylpyrrolidone, dimethylsulfoxide (DMSO), diethylene glycol monoethyl ethers, capryl ocaproyl polyoxyl-8 glycerides, glycofurol, or mixtures thereof.
In some embodiments, the co-solvent can be present in an about 3% to about 80% of the total weight of the formulation, preferably from about 3% to about 50% of the total weight of the formulation, more preferably from about 3% to about 30% of the total weight of the formulation and most preferably from about 3% to about 25% of the total weight of the formulation.
The co-solvent is preferably selected from the group consisting of alcohol, polyethylene glycols, propylene glycol and mixtures thereof. Preferably, the polyethylene glycol has a molecular weight in the range from 200 to 600. More preferably, the polyethylene glycol has a molecular weight of about 300 (PEG 300). In some ready-to-dilute (pre-concentrate) embodiments, the co-solvent can be present in an about 5% to about 70% of the total weight of the formulation, preferably from about 10% to about 50% of the total weight of the formulation, more preferably from about 15% to about 30% of the total weight of the formulation and most preferably from about 20% to about 25% of the total weight of the formulation.
In some ready -to-administer/use (RTU) embodiments, the co-solvent can be present in an about 0% to about 10% of the total weight of the formulation, preferably from about 2% to about 7% of the total weight of the formulation, more preferably from about 3% to about 6% of the total weight of the formulation and most preferably from about 4% to about 5% of the total weight of the formulation. Formulation containing high concentration of co-solvent resulted in high viscosity of the solution, while formulations having low concentration had tendency for precipitation of remdesivir during storage. Hence, appropriate concentration of cosolvent is necessary to maintain remdesivir in solution state during shelf life of the product and in-use period while avoiding the high viscous solution. The formulations may include one or more buffering agents. In certain embodiments, the buffering agent comprises a Cl-6alkyl carboxylic acid, for instance formic acid, acetic acid, 1 -propionic acid, 2-propionic acid, n-butyric acid, t-butyric acid, isobutyric acid, or sec-butyric acid. In some embodiments, the buffering agent comprises a hydroxy substituted-carboxylic acid or polycarboxylic acid, e.g., a compound having two or more carboxylic acid functional groups. Such compounds include, for instance, lactic acid, glycolic acid, 3 -hydroxypropionic acid, hydroxylbutyric acid, malonic acid, succinic acid, malic acid, tartaric acid, citric acid, fumaric acid, muramic acid, gluconic acid and glucuronic acid.
The acid buffering agent or acidifying agents may be present in an amount in the range from about 0.01% to about 2% of the total weight of the formulation.
Generally, the formulations disclosed herein will not contain any cyclodextrin compounds. As used herein, the term “cyclodextrin” refers to any cyclic compound composed of multiple carbohydrate (e.g., glucopyranoside) units. Remdesivir in formulations disclosed herein has substantially the same solubility and pharmacokinetic behavior as remdesivir complexed with cyclodextrin.
The pharmaceutical composition of present invention further comprises antioxidant. Suitable antioxidants include those, although not limited to ,
monothioglycerol, L-cysteine and thioglycolic acid, selected from the group comprising of acetyl cysteine, butylated hydroxy toluene, butylated hydroxy anisole, DL-tocopherol, sodium metabisulfite, sodium formaldehyde sulfoxylate, EDTA and its derivatives, methionine, ascorbic acid, citric acid and its pharmaceutically acceptable salt, sodium sulfite and its derivative and the like.
The antibacterial preservatives, that can be included in the present invention are, but not limited to, one or more of phenylmercuric nitrate, thiomersal, benzalkonium chloride, benzethonium chloride, phenol, cresol, chlorobutanol, benzyl alcohol, parabens and combination thereof.
According to the present invention, there is provided a process of preparing a pharmaceutical composition comprising remdesivir with one or more pharmaceutically acceptable excipients.
According to preferred embodiment of the present invention, the pharmaceutical composition may involve dissolution of remdesivir in suitable excipients like surfactants, co-solvents mixture containing buffering agent followed by other excipients osmolality agents and pH adjusting agents and making up of the volume with suitable solvent and filling in suitable containers like ampoule or vials or plastic bags. The containers may or may not require any form of sterilization.
According to the invention, there is provided a pharmaceutical composition comprising remdesivir with one or more pharmaceutically acceptable excipients for the treatment of infection caused COVID-19.
It may be well appreciated by a person skilled in the art that the pharmaceutical composition comprising remdesivir may require specific dosage amounts and specific frequency of administrations specifically considering their individual established doses, the dosing frequency, patient adherence and the regimen adopted. As described herein, considering that there are various parameters to govern the
dosage and administration of the composition as per the present invention, it would be well acknowledged by a person skilled in the art to exercise caution with respect to the dosage, specifically, for special populations associated with other disorders. In order that this invention be more fully understood, the following preparative and testing methods and examples are set forth. The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the present invention.
EXAMPLES
Screening experiments:
Preliminary screening experiments (Table 1) were performed to understand the solubility of Remdesivir in the co-solvent and surfactant combinations.
These experiments (Formula - 1 and Formula - 2) indicated that a stable composition can be formulated which does not exhibit precipitation upon further dilution with 0.9% saline solution. The limitation/drawback of these formulations are usage of higher amounts of Polysorbate 80.
Considering the maximum daily dose of 200 mg Remdesivir, the above compositions (Formula -1 & Formula 2) with 26% Polysorbate 80 would corresponds to a daily intake of about 10.4 g of Polysorbate 80. An intake of <4.5g/day is preferred considering the level of Polysorbate 80 approved in the marketed products.
Effect of Surfactant concentration:
Set of experiments were designed and to study the effect of polysorbate 80 concentration on stability of formulation to maintain Remdesivir in solution state without precipitation during storage and in-use period upon dilution using 0.9% saline solution.
Formula 3 experiment was conducted to understand the effect of additional cosolvent i.e. propylene glycol in absence of surfactant, polysorbate 80. Precipitation was observed within 24 hours. This experiment highlights the need of presence of effective concentration of Polysorbate 80 for formulating stable composition.
These experiments highlight the significance of surfactant concentration in the formulation stability. Maintenance of adequate surfactant concentration is necessary to stabilize the formulation and to avoid precipitation. Formulations up to 6.5% w/v polysorbate have a precipitation tendency during storage. It was
surprisingly observed that a stable Remdesvir formulations can be achieved even with lower level of Polysorbate 80 when maintained at about 10% w/v & about 20% w/v, the formulations are stable during storage, without any precipitation tendency even after dilution with saline solution.
These experiments demonstrate that the optimal concentration of surfactant, polysorbate 80 is required for maintaining the stability of Remdesivir formulation and manifests that solubilization of Remdesivir is mainly through micellar solubilization.
Effect of co-solvent and buffer concentration:
Set of experiments were conducted to understand the role of co-solvent, i.e. Polyethylene glycol 300 concentration and buffering agent, Citric acid concentration on stability of formulation.
These experiments (Formula 8 and Formula 9) indicated that appropriate level of cosolvent concentration and buffering/ pH adjusting agent (to maintain pH) is necessary to maintain stability of Remdesivir in solution state during storage.
From the above set of experiments, the formula 6 is found to be promising and considered as a prototype formula and is detailed below.
READY-TO-DILUTE (RTD) FORMULATION
Considering the maximum daily dose of 200 mg Remdesivir, the prototype formula (Formula 6) with 10% polysorbate 80 would corresponds to a daily intake of about 4.0 g of Polysorbate 80. An intake of <4.5g/day is preferred considering the level of Polysorbate 80 approved in the marketed products (Amiodarone Injection 50mg/mL &Docetaxel injection 20mg/mL) Hence, the optimized concentration of polysorbate 80 and other excipients are well within the level used in other approved formulations.
Manufacturing Process:
1) Polyethylene glycol and Polysorbate 80 were mixed followed by addition of Citric acid to obtain a clear solution.
2) Remdesivir was added to the solution obtained in step (1) and mixed for NLT 1 hour to obtain a clear solution.
3) Volume was made up using Water for Injection to 95% batch volume.
4) The pH was adjusted to 3.0 to 4.5 using sodium hydroxide and/or hydrochloric acid and finally volume is made up to batch volume using Water for Injection to yield a 5 mg/ml solution of Remdesivir.
5) The solution was filtered through 0.2p PES filters and filled in 20 mL USP Type 1 glass vials, stoppered using butyl rubber stopper and sealed using aluminum flip-off seals.
Stability evaluation of prototype formulations:
Batches were manufactured with Formula - 6 composition and pH was varied to understand the effect of pH of the formulation. The batches were loaded onto long term (2°-8°C) and accelerated (25°C/60%RH) storage conditions. The stability of the formulations were compared with a typical formulation containing Cyclodextrin as solubilizer, similar to Reference product, Veklury.
Reference product information (Formulation containing Cyclodextrin)
The Reference Listed Drug (RLD) is Veklury (Remdesivir) 100mg/20mL (5mg/mL), which was approved on Oct 22, 2020 in United States and application holder is Gilead sciences INC. Inactive ingredients in Veklury injection are 6 g betadex sulfobutyl ether sodium, Water for Injection, USP, and may include hydrochloric acid and/or sodium hydroxide for pH adjustment. Betadex sulfobutyl ether sodium (Cyclodextrin) acts as solubilizer in this formulation. Recommended storage condition of Veklury is “Store at refrigerated temperature (2°C to 8°C)”.
The following Table provides comparative stability of the prototype formula - 6 at different solution pH and a formulation manufactured using quantitative formula provided in label of Reference product, Veklury® at room temperature conditions. Table 5. Comparative Stability data of Cyclodextrin- free formulations at room temperature conditions (25°C/60%RH) in inverted orientation
Based on 6 months data at room temperature condition (25°/60%RH), it can be inferred that prototype cyclodextrin free formulation, especially the formulation at pH about 4 exhibits comparable or improved stability when compared to current cyclodextrin formulations indicating pH dependent stability of the formulation.
Stability evaluation at long term refrigeration (2°-8°C):
Further, the comparative stability of the prototype formulation at long term refrigeration storage condition (2°-8°C) is provided in Table 6.
Table 6. Comparative Stability data of Cyclodextrin- free formulations at refrigeration storage conditions (2°C to 8°C) in inverted orientation
Based on 6 months data at long term refrigeration storage condition (2°-8°C), it was observed that the prototype cyclodextrin-free formulation exhibits comparable or improved stability when compared to formulation containing cyclodextrin. The proposed prototype formulation is found to be accommodate longer exposure to room temperature storage conditions during in-use or during transportation.
Ready to use (RTU) Formulations
Based on the observations/learnings from Ready to dilute (RTD) concentrate formulations, a cyclodextrin-free ready-to use (RTU) formulation was developed, which saves time during administration at hospital setup and reduces dosing errors. In ready to use formulation, the prototype formula (Formula 10) is designed to yield 1 mg/mL of Remdesivir. Appropriate quantity of sodium chloride or dextrose can be added to maintain isotonicity.
Manufacturing Process:
1) Polyethylene glycol and Polysorbate 80 were mixed followed by addition of Citric acid to obtain a clear solution.
2) Remdesivir was added to the solution obtained in step (1) and mixed for NLT 1 hour to obtain a clear solution.
3) Volume was made up using Water for Injection to 95% batch volume and sodium chloride (when applicable) was added and mixed to obtain a clear solution.
4) The pH was adjusted to 3.0 to 4.5 using sodium hydroxide and/or hydrochloric acid and finally volume is made up to batch volume using Water for Injection to yield a 1 mg/ml solution of Remdesivir.
5) The solution was filtered through 0.2p PES filters and was filled in 100 mL USP Type 1 glass vials, stoppered using butyl rubber stopper and sealed using aluminum flip-off seals
The stability of the formulation at room temperature conditions (25°C/60%RH) at inverted orientation was evaluated and is provided in Table 8.
@ Testing not performed
Based on 3 months data at 25°C/60%RH, all physico-chemical test parameters are within the specified limits. It can be inferred that cyclodextrin free ready to use formulation is stable that could potentially support an extended in-use and transportation at room temperature conditions.
Claims
1. A ready -to-dilute or ready -to-use pharmaceutical formulations free of cyclodextrins comprising remdisivir or a pharmaceutically acceptable derivative thereof and one more pharmaceutically acceptable excipients.
2. The pharmaceutical composition according to claim 1, wherein the one or more pharmaceutically acceptable excipients are selected from pH adjusting agent, buffer, osmotic agent, surfactant, antioxidant, co-solvent, preservative, and/or isotonicity agent.
3. The pharmaceutical composition according to claim 1, wherein the surfactant is selected from the group comprising non-ionic surfactants.
4. The pharmaceutical composition according to claim 3, wherein the surfactant is polysorbate 80 and/ or Polysorbate 20.
5. The pharmaceutical composition according to claim 3 and 4, wherein the surfactant is present from about 8% to about 12% of the total weight of the composition.
6. The pharmaceutical composition according to claim 1, wherein the cosolvent is selected from the group comprising ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerol, dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide, diethylene glycol monoethyl ethers, caprylocaproyl polyoxyl-8 glycerides, glycofurol or combinations thereof.
7. The pharmaceutical composition according to claim 6, wherein the cosolvent is polyethylene glycol and/or propylene glycol.
8. The pharmaceutical composition according to claim 6 and 7, wherein the co-solvent is present from about 4% to about 25% of the total weight of the composition.
9. The pharmaceutical composition according to claim 1, wherein the buffer is selected from the group comprising formic acid, acetic acid, 1 -propionic acid, 2-propionic acid, n-butyric acid, t-butyric acid, isobutyric acid, or secbutyric acid, lactic acid, glycolic acid, 3 -hydroxypropionic acid,
28
hydroxylbutyric acid, malonic acid, succinic acid, malic acid, tartaric acid, citric acid, fumaric acid, muramic acid, gluconic acid and glucuronic acid or combinations thereof.
10. The pharmaceutical composition according to claim 9, wherein the buffer is present from about 0.01% to about 2% of the total weight of the composition.
11. The pharmaceutical composition according to claim 1 wherein the pH of the composition is from about 3 to about 7.
12. The pharmaceutical composition according to claim 1 which is in a form suitable for parenteral administration.
13. The pharmaceutical composition according to claim 1 which is meant for long term storage.
14. A method of preparing a pharmaceutical composition comprising the steps of:
(a) dissolving remdesivir or pharmaceutically acceptable derivative thereof in suitable excipients like surfactants, co-solvents mixture containing buffering agent to form a solution;
(b) adjusting the pH of the solution.
15. A method for treating COVID-19 comprising administering a pharmaceutical composition according to claim 1 to a subject in need thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202021046615 | 2020-10-26 | ||
IN202021046615 | 2020-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022091122A1 true WO2022091122A1 (en) | 2022-05-05 |
Family
ID=81382081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2021/051012 WO2022091122A1 (en) | 2020-10-26 | 2021-10-26 | Stable remdesivir formulations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022091122A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076878A1 (en) * | 2021-10-26 | 2023-05-04 | Emphascience Inc. | Ready-to-dilute formulation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019018185A1 (en) * | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane derivatives for the treatment of filovirus infection |
US20200237689A1 (en) * | 2018-11-15 | 2020-07-30 | Bluewillow Biologics, Inc. | Prevention and treatment of coronavirus and other respiratory infections using nanoemulsion compositions |
-
2021
- 2021-10-26 WO PCT/IN2021/051012 patent/WO2022091122A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019018185A1 (en) * | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane derivatives for the treatment of filovirus infection |
US20200237689A1 (en) * | 2018-11-15 | 2020-07-30 | Bluewillow Biologics, Inc. | Prevention and treatment of coronavirus and other respiratory infections using nanoemulsion compositions |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076878A1 (en) * | 2021-10-26 | 2023-05-04 | Emphascience Inc. | Ready-to-dilute formulation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9358297B2 (en) | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | |
US7772274B1 (en) | Docetaxel formulations with lipoic acid | |
US20120142768A1 (en) | Formulations including amiodarone and salts thereof and methods of their manufacture and use | |
CN107810000B (en) | Injectable pharmaceutical composition of leflunomide | |
WO2009097443A2 (en) | Liquid formulations of compounds active at sulfonylurea receptors | |
US20210378988A1 (en) | Phytonadione compositions and related methods | |
WO2022091122A1 (en) | Stable remdesivir formulations | |
AU2011273064A1 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
CN102958519A (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
EP3509569A1 (en) | Sterile injectable compositions comprising drug micelles | |
US8476310B2 (en) | Docetaxel formulations with lipoic acid | |
US11865206B2 (en) | Stable ready-to-use carmustine pharmaceutical composition | |
JP6033931B2 (en) | Organic solvent-free gemcitabine aqueous solution composition | |
WO2017007805A1 (en) | Intravenous formulations of a late sodium current inhibitor | |
BR102019004382A2 (en) | INJECTABLE STERILE COMPOSITION | |
JP2015000869A (en) | Organic solvent-free gemcitabine aqueous solution composition | |
WO2016079749A2 (en) | Process for preparation of parenteral formulation of anidulafungin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21885543 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21885543 Country of ref document: EP Kind code of ref document: A1 |